🟢 EIQ.XA is trading 36% up today after key U.S. leadership appointments for commercial expansion

EIQ.XA is trading 36% up today at A$1.69 after announcing major U.S.-focused leadership changes to support FDA initiatives and commercial expansion.

• Echo IQ appointed Matthew Dodds as Chief Financial Officer (effective June 2026) and heart specialist Dr. Vinod Thourani as a senior clinical advisor.
• The leadership reshuffle is designed to strengthen the company's finance and clinical benches ahead of accelerated U.S. growth and regulatory milestones.
• Investors are interpreting the move as a strong signal of intent for the company's international scaling and U.S. market penetration strategy.